Auxilium Pharmaceuticals Increases Sales but Misses Estimates on Earnings
Auxilium Pharmaceuticals (NAS: AUXL) reported earnings on Nov. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Auxilium Pharmaceuticals whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP loss per share grew.
Margins dropped across the board.
Auxilium Pharmaceuticals booked revenue of $71.0 million. The 13 analysts polled by S&P Capital IQ hoped for sales of $79.5 million on the same basis. GAAP reported sales were 6.4% higher than the prior-year quarter's $66.7 million.
EPS came in at -$0.21. The 12 earnings estimates compiled by S&P Capital IQ anticipated -$0.07 per share. GAAP EPS were -$0.21 for Q3 against -$0.08 per share for the prior-year quarter.
For the quarter, gross margin was 77.7%, 200 basis points worse than the prior-year quarter. Operating margin was -15.1%, 880 basis points worse than the prior-year quarter. Net margin was -14.8%, 870 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $87.2 million. On the bottom line, the average EPS estimate is -$0.06.
Next year's average estimate for revenue is $322.5 million. The average EPS estimate is -$0.04.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 123 members out of 178 rating the stock outperform, and 55 members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Auxilium Pharmaceuticals a green thumbs-up, and 26 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $26.18.
- Add Auxilium Pharmaceuticals to My Watchlist.
The article Auxilium Pharmaceuticals Increases Sales but Misses Estimates on Earnings originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.